227 related articles for article (PubMed ID: 35109713)
1. Class-Based Antiretroviral Exposure and Cognition Among Women Living with HIV.
Spence AB; Liu C; Rubin L; Aouizerat B; Vance DE; Bolivar H; Lahiri CD; Adimora AA; Weber K; Gustafson D; Sosanya O; Turner RS; Kassaye S
AIDS Res Hum Retroviruses; 2022 Jul; 38(7):561-570. PubMed ID: 35109713
[TBL] [Abstract][Full Text] [Related]
2. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
3. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.
; Babiker A; Castro nee Green H; Compagnucci A; Fiscus S; Giaquinto C; Gibb DM; Harper L; Harrison L; Hughes M; McKinney R; Melvin A; Mofenson L; Saidi Y; Smith ME; Tudor-Williams G; Walker AS
Lancet Infect Dis; 2011 Apr; 11(4):273-83. PubMed ID: 21288774
[TBL] [Abstract][Full Text] [Related]
4. Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey.
Musengimana G; Tuyishime E; Kiromera A; Malamba SS; Mulindabigwi A; Habimana MR; Baribwira C; Ribakare M; Habimana SD; DeVos J; Mwesigwa RCN; Kayirangwa E; Semuhore JM; Rwibasira GN; Suthar AB; Remera E
Antivir Ther; 2022 Jun; 27(3):13596535221102690. PubMed ID: 35593031
[TBL] [Abstract][Full Text] [Related]
5. Associations between Antiretrovirals and Cognitive Function in Women with HIV.
Rubin LH; Li Y; Fitzgerald KC; Dastgheyb R; Spence AB; Maki PM; Sharma A; Gustafson DR; Milam J; Weber KM; Adimora AA; Haughey NJ; Ofotokun I; Fischl MA; Konkle-Parker D; Xu Y; Williams DW
J Neuroimmune Pharmacol; 2021 Mar; 16(1):195-206. PubMed ID: 32212091
[TBL] [Abstract][Full Text] [Related]
6. The Prevalence and Burden of Non-AIDS Comorbidities Among Women Living With or at Risk for Human Immunodeficiency Virus Infection in the United States.
Collins LF; Sheth AN; Mehta CC; Naggie S; Golub ET; Anastos K; French AL; Kassaye S; Taylor T; Fischl MA; Adimora AA; Kempf MC; Palella FJ; Tien PC; Ofotokun I
Clin Infect Dis; 2021 Apr; 72(8):1301-1311. PubMed ID: 32115628
[TBL] [Abstract][Full Text] [Related]
7. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
[TBL] [Abstract][Full Text] [Related]
8. Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium.
Byonanebye DM; Polizzotto MN; Neesgaard B; Sarcletti M; Matulionyte R; Braun DL; Castagna A; de Wit S; Wit F; Fontas E; Vehreschild JJ; Vesterbacka J; Greenberg L; Hatleberg C; Garges H; Gallant J; Volny Anne A; Öllinger A; Mozer-Lisewska I; Surial B; Spagnuolo V; Necsoi C; van der Valk M; Mocroft A; Law M; Ryom L; Petoumenos K;
HIV Med; 2022 Sep; 23(8):895-910. PubMed ID: 35233903
[TBL] [Abstract][Full Text] [Related]
9. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
[TBL] [Abstract][Full Text] [Related]
10. Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels compared to protease inhibitor-based therapy.
Pasternak AO; Vroom J; Kootstra NA; Wit FW; de Bruin M; De Francesco D; Bakker M; Sabin CA; Winston A; Prins JM; Reiss P; Berkhout B;
Elife; 2021 Aug; 10():. PubMed ID: 34387543
[TBL] [Abstract][Full Text] [Related]
11. Plasma Biomarkers of Alzheimer Disease in Women With and Without HIV.
Li X; Yucel R; Clervius H; Kamalakar K; Zetterberg H; Blennow K; Zhang J; Adimora A; Collins LF; Fischl M; Kassaye S; Maki P; Seaberg E; Sharma A; Vance D; Gustafson DR
JAMA Netw Open; 2023 Nov; 6(11):e2344194. PubMed ID: 38019518
[TBL] [Abstract][Full Text] [Related]
12. Adverse perinatal outcomes associated with prenatal exposure to protease-inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based antiretroviral combinations in pregnant women with HIV infection: a systematic review and meta-analysis.
Saint-Lary L; Benevent J; Damase-Michel C; Vayssière C; Leroy V; Sommet A
BMC Pregnancy Childbirth; 2023 Jan; 23(1):80. PubMed ID: 36717801
[TBL] [Abstract][Full Text] [Related]
13. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV.
Kline MDA; Daniels C; Xu X; Sunil T; Ganesan A; Agan BK; Colombo RE; Kronmann KC; Blaylock JM; Okulicz JF; Markelz AE
Mil Med; 2021 Feb; 186(3-4):279-285. PubMed ID: 33128552
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of 2-drug regimen users living with HIV-1 in a real-world setting: A large-scale medical claim database analysis in Japan.
Ruzicka DJ; Kamakura M; Kuroishi N; Oshima N; Yamatani M; Yi J; Crawford B; Tsukada K; Oka S
PLoS One; 2022; 17(6):e0269779. PubMed ID: 35700215
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis.
Snedecor SJ; Radford M; Kratochvil D; Grove R; Punekar YS
BMC Infect Dis; 2019 May; 19(1):484. PubMed ID: 31146698
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy and neonatal outcomes in women with HIV-1 exposed to integrase inhibitors, protease inhibitors and non-nucleoside reverse transcriptase inhibitors: an observational study.
Floridia M; Dalzero S; Giacomet V; Tamburrini E; Masuelli G; Savasi V; Spinillo A; Tassis B; Franceschetti L; Degli Antoni AM; Sansone M; Guaraldi G; Vimercati A; Meloni A; Ravizza M;
Infection; 2020 Apr; 48(2):249-258. PubMed ID: 31893354
[TBL] [Abstract][Full Text] [Related]
18. Rate of dyslipidemia higher among women living with HIV: A comparison of metabolic and cardiovascular health in a cohort to study aging in HIV.
Russell E; Albert A; Côté H; Hsieh A; Nesbitt A; Campbell AR; Maan EJ; Brophy J; Pick N; Murray M
HIV Med; 2020 Aug; 21(7):418-428. PubMed ID: 32168418
[TBL] [Abstract][Full Text] [Related]
19. Long-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings.
Lima VD; Hull M; McVea D; Chau W; Harrigan PR; Montaner JS
J Int AIDS Soc; 2016; 19(1):20978. PubMed ID: 27499064
[TBL] [Abstract][Full Text] [Related]
20. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
